A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID - Nature Communications A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle that P...

Thrilled to share our paper in Nature Communications – A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. #LongCOVID #PLpro #COVID19 #SARSCoV2 #Antivirals www.nature.com/articles/s41...